Cargando…

The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats

BACKGROUND: Sodium glucose co-transporter 2 inhibitor (SGLT2i), a new class of anti-diabetic drugs acting on inhibiting glucose resorption by kidneys, is shown beneficial in reduction of heart failure hospitalization and cardiovascular mortality. The mechanisms remain unclear. We hypothesized that S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hsiang-Chun, Shiou, Yi-Lin, Jhuo, Shih-Jie, Chang, Chia-Yuan, Liu, Po-Len, Jhuang, Wun-Jyun, Dai, Zen-Kong, Chen, Wei-Yu, Chen, Yun-Fang, Lee, An-Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444638/ https://www.ncbi.nlm.nih.gov/pubmed/30935417 http://dx.doi.org/10.1186/s12933-019-0849-6

Ejemplares similares

Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin
por: Jhuo, Shih-Jie, et al.
Publicado: (2021)

Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats
por: Lee, Ting-I, et al.
Publicado: (2019)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
por: Li, Chenguang, et al.
Publicado: (2019)

Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
por: van der Hoek, Sjoukje, et al.
Publicado: (2023)

Empagliflozin and Renal Sodium-Hydrogen Exchange in Healthy Subjects
por: Biancalana, Edoardo, et al.
Publicado: (2023)

Intravital imaging of hemodynamic glomerular effects of enalapril or/and empagliflozin in STZ-diabetic mice
por: Kroeger, Hannah, et al.
Publicado: (2022)

Simvastatin Attenuates Cardiac Fibrosis via Regulation of Cardiomyocyte-Derived Exosome Secretion
por: Kuo, Hsuan-Fu, et al.
Publicado: (2019)

Attenuation of Adverse Postinfarction Left Ventricular Remodeling with Empagliflozin Enhances Mitochondria-Linked Cellular Energetics and Mitochondrial Biogenesis
por: Song, Yang, et al.
Publicado: (2021)

Impact of diabetes duration on left ventricular mass regression with empagliflozin
por: Moroney, Michael, et al.
Publicado: (2023)

Exercise Attenuates Intermittent Hypoxia-Induced Cardiac Fibrosis Associated with Sodium-Hydrogen Exchanger-1 in Rats
por: Chen, Tsung-I, et al.
Publicado: (2016)

QTc Interval is Associated with Atrial Fibrillation in Individuals with Metabolic Syndrome Phenotype
por: Lee, Ming-Chuan, et al.
Publicado: (2022)

Sodium–Glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice
por: Xue, Genlong, et al.
Publicado: (2022)

Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis
por: Chung, Cheng-Chih, et al.
Publicado: (2023)

Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
por: Boorsma, Eva M., et al.
Publicado: (2020)

Video-Twin Technique for Airway Management, Combining Video-Intubating Stylet with Videolaryngoscope: A Case Series Report and Review of the Literature
por: Jhuang, Bo-Jyun, et al.
Publicado: (2022)

Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis
por: Zou, Rongjun, et al.
Publicado: (2022)

Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin
por: Philippaert, Koenraad, et al.
Publicado: (2021)

Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats
por: Trang, Nguyen Ngoc, et al.
Publicado: (2021)

Empagliflozin Ameliorates Diabetic Cardiomyopathy via Attenuating Oxidative Stress and Improving Mitochondrial Function
por: Wang, Jinwu, et al.
Publicado: (2022)

Empagliflozin and Dulaglutide are Effective against Obesity-induced Airway Hyperresponsiveness and Fibrosis in A Murine Model
por: Park, Hye Jung, et al.
Publicado: (2019)

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin
por: Puar, Pankaj, et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
por: Scheen, André J.
Publicado: (2014)

Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin
por: Sanon, Vani P, et al.
Publicado: (2017)

Acute interstitial nephritis due to sodium-glucose co-transporter 2 inhibitor empagliflozin
por: Ryan, Rebecca, et al.
Publicado: (2020)

Empagliflozin/insulin/sodium bicarbonate: Euglycaemic diabetic ketoacidosis and lack of efficacy: case report
Publicado: (2022)

Empagliflozin Inhibits Cardiac Late Sodium Current by Ca/Calmodulin-Dependent Kinase II
por: Mustroph, Julian, et al.
Publicado: (2022)

Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats
por: Kuno, Atsushi, et al.
Publicado: (2020)

Single Junction Inverted Polymer Solar Cell Reaching Power Conversion Efficiency 10.31% by Employing Dual-Doped Zinc Oxide Nano-Film as Cathode Interlayer
por: Liao, Sih-Hao, et al.
Publicado: (2014)

Direct Cardiac Actions of the Sodium Glucose Co‐Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure‐Overload Heart Failure
por: Li, Xuan, et al.
Publicado: (2021)

Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction
por: Lee, Soo Yong, et al.
Publicado: (2020)

Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
por: Gallo, Linda A., et al.
Publicado: (2016)

Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation
por: Lu, Chia-Wen, et al.
Publicado: (2023)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
por: Wang, Dong-Dong, et al.
Publicado: (2022)

Effect of Empagliflozin, a Selective Sodium-Glucose Cotransporter 2 Inhibitor, on Kidney and Peripheral Nerves in Streptozotocin-Induced Diabetic Rats
por: Lee, Kyung Ae, et al.
Publicado: (2018)

Empagliflozin reduces Ca/calmodulin‐dependent kinase II activity in isolated ventricular cardiomyocytes
por: Mustroph, Julian, et al.
Publicado: (2018)

Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes
por: Sarak, Bradley, et al.
Publicado: (2021)

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
por: Butler, Javed, et al.
Publicado: (2021)

Machine Learning Quantitative Analysis of FDG PET Images of Medial Temporal Lobe Epilepsy Patients
por: Shih, Yen-Cheng, et al.
Publicado: (2022)

Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes
por: Bjornstad, Petter, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_61esk01nu00o9jmr62ng7s6e5l